Title : The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia.

Pub. Date : 2018 May 31

PMID : 29857559






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia. RG7388 FMS-like tyrosine kinase 3 Mus musculus
2 Our data indicate that AML cells with normal karyotype (NK) and wild-type status of TP53 with elevated FLT3 and MDM2 expression emerge to be most sensitive to the combined treatment with cobimetinib and idasanutlin. RG7388 FMS-like tyrosine kinase 3 Mus musculus
3 FLT3 and MDM2 are biomarkers for treatment response to idasanutlin and cobimetinib in AML. RG7388 FMS-like tyrosine kinase 3 Mus musculus